CN102321577B - 抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 - Google Patents
抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 Download PDFInfo
- Publication number
- CN102321577B CN102321577B CN 201110028478 CN201110028478A CN102321577B CN 102321577 B CN102321577 B CN 102321577B CN 201110028478 CN201110028478 CN 201110028478 CN 201110028478 A CN201110028478 A CN 201110028478A CN 102321577 B CN102321577 B CN 102321577B
- Authority
- CN
- China
- Prior art keywords
- cell
- cik
- preparation
- day
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 14
- 210000002865 immune cell Anatomy 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 35
- 108090000695 Cytokines Proteins 0.000 claims abstract description 25
- 102000004127 Cytokines Human genes 0.000 claims abstract description 25
- 238000012258 culturing Methods 0.000 claims abstract description 20
- 230000001939 inductive effect Effects 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 17
- 230000011748 cell maturation Effects 0.000 claims description 16
- 230000036039 immunity Effects 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 13
- 230000003203 everyday effect Effects 0.000 claims description 12
- 230000006698 induction Effects 0.000 claims description 12
- 102000011961 Maturation-Promoting Factor Human genes 0.000 claims description 11
- 108010075942 Maturation-Promoting Factor Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 108010056030 retronectin Proteins 0.000 claims description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 239000006166 lysate Substances 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 230000004041 dendritic cell maturation Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 11
- 238000005070 sampling Methods 0.000 abstract description 3
- 210000005259 peripheral blood Anatomy 0.000 abstract description 2
- 239000011886 peripheral blood Substances 0.000 abstract description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 16
- 239000002504 physiological saline solution Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110028478 CN102321577B (zh) | 2011-01-26 | 2011-01-26 | 抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110028478 CN102321577B (zh) | 2011-01-26 | 2011-01-26 | 抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102321577A CN102321577A (zh) | 2012-01-18 |
CN102321577B true CN102321577B (zh) | 2013-09-11 |
Family
ID=45449415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110028478 Expired - Fee Related CN102321577B (zh) | 2011-01-26 | 2011-01-26 | 抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102321577B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102978161A (zh) * | 2012-10-24 | 2013-03-20 | 江阴齐氏生物科技有限公司 | Dc-cik细胞分离培养试剂盒及其应用 |
CN102978159A (zh) * | 2012-11-22 | 2013-03-20 | 深圳市中美康士生物科技有限公司 | 增强cik细胞增殖能力及提高杀死肿瘤细胞的方法 |
CN103525763A (zh) * | 2013-09-28 | 2014-01-22 | 青岛麦迪赛斯生物科技有限公司 | 一种高效cik细胞的培养方法 |
CN103642752A (zh) * | 2013-12-04 | 2014-03-19 | 深圳市合一康生物科技有限公司 | 人cd3+cd8+cik细胞的制备方法 |
CN103642754A (zh) * | 2013-12-04 | 2014-03-19 | 深圳市合一康生物科技有限公司 | 一种高毒性、高增值能力的人d-cik细胞的制备方法 |
CN103756960A (zh) * | 2013-12-04 | 2014-04-30 | 深圳市合一康生物科技有限公司 | 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒 |
CN103642753A (zh) * | 2013-12-04 | 2014-03-19 | 深圳市合一康生物科技有限公司 | 人cd3+cd8+cik细胞制备的专用试剂盒 |
CN103981144B (zh) * | 2014-03-17 | 2017-06-06 | 深圳市合一康生物科技股份有限公司 | 自体血清抗原致敏dc‑cik细胞的制备方法 |
CN105154398A (zh) * | 2015-07-17 | 2015-12-16 | 深圳爱生再生医学科技有限公司 | Cik及其制备方法 |
CN106190973B (zh) * | 2016-07-07 | 2019-07-19 | 北京景达生物科技有限公司 | 一种nkt细胞培养方法 |
CN109535241B (zh) * | 2018-12-18 | 2021-01-08 | 北昊干细胞与再生医学研究院有限公司 | Dc-cik共培养细胞及其制备方法、致敏抗原和应用 |
CN114107202B (zh) * | 2021-12-08 | 2023-08-22 | 杭州中赢生物医疗科技有限公司 | 一种免疫细胞及其制备方法与应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1431298A (zh) * | 2003-01-30 | 2003-07-23 | 中国科学院上海生命科学研究院 | 一种抗肿瘤免疫活性细胞-dcik细胞、其制备方法及应用 |
CN1869206A (zh) * | 2006-05-27 | 2006-11-29 | 大连理工大学 | 一种高效免疫活性细胞群制备及用于抗肿瘤的方法 |
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN101519646A (zh) * | 2009-02-06 | 2009-09-02 | 上海德嘉生物科技有限公司 | 一种cik细胞及其制备方法和细胞制剂 |
-
2011
- 2011-01-26 CN CN 201110028478 patent/CN102321577B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1431298A (zh) * | 2003-01-30 | 2003-07-23 | 中国科学院上海生命科学研究院 | 一种抗肿瘤免疫活性细胞-dcik细胞、其制备方法及应用 |
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN1869206A (zh) * | 2006-05-27 | 2006-11-29 | 大连理工大学 | 一种高效免疫活性细胞群制备及用于抗肿瘤的方法 |
CN101519646A (zh) * | 2009-02-06 | 2009-09-02 | 上海德嘉生物科技有限公司 | 一种cik细胞及其制备方法和细胞制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102321577A (zh) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102321577B (zh) | 抗肿瘤过继免疫细胞制备方法及制得的免疫细胞 | |
CN109294985B (zh) | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 | |
CN102174469B (zh) | 一种有效培养肿瘤浸润淋巴细胞的方法 | |
CN103923880B (zh) | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 | |
CN107326008A (zh) | 一种从外周血中高效高纯度扩增自然杀伤细胞的方法 | |
CN105062968B (zh) | 一种dc-cik细胞培养试剂及其培养方法 | |
CN103756963A (zh) | 一种体外扩增nk细胞的方法 | |
CN107541498A (zh) | 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途 | |
CN104815323B (zh) | 一种树突状细胞肿瘤疫苗及其制备方法 | |
CN105087487A (zh) | 一种高效扩增cik的方法 | |
CN105018424A (zh) | Dc-cik细胞及其制备方法 | |
CN102321581A (zh) | 腹水肿瘤细胞致敏dc-cik的制备方法 | |
CN105219708A (zh) | 免疫细胞培养试剂盒、免疫细胞培养方法和应用 | |
JP2017012010A (ja) | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 | |
CN102827809B (zh) | 高增殖能力、高细胞毒活性、高存活率的cik细胞制备方法、相关cik细胞及应用 | |
CN105176926A (zh) | 一种体外培养扩增nk细胞的方法 | |
CN105238753A (zh) | 一种用于制备ctl的试剂盒及其应用 | |
CN105802908A (zh) | 一种体外制备肿瘤抗原特异性cd8+干细胞样记忆性t淋巴细胞的方法 | |
CN103981144A (zh) | 自体血清抗原致敏dc-cik细胞的制备方法 | |
CN105505871A (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN103740643B (zh) | 一种mhc限制性杀伤t细胞的体外诱导培养方法 | |
WO2016201658A1 (zh) | 一种肿瘤特异性 ctl 的制备方法 | |
CN103834614A (zh) | 一种附子多糖诱导nkt细胞增殖的制备方法及其应用 | |
US20220177839A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
CN105039254B (zh) | 一种免疫细胞及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Xiaoxiang Inventor after: Shen Zheng Inventor before: Li Xiaoxiang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI XIAOXIANG TO: LI XIAOXIANG SHEN ZHENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 518057 Guangdong Province, Shenzhen city Nanshan District District Science Park North Road Song Ping Road No. 1 Lite Technology Building South 707 Patentee after: ZMKS International Cancer Therapy Biotechnologies Co., Ltd. Address before: 518057 No. 19, Lang Lang Road, Nanshan District hi tech park, Guangdong, Shenzhen, China Patentee before: ZMKS International Cancer Therapy Biotechnologies Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130911 Termination date: 20210126 |